BTC $79,703.19 -1.82%
ETH $2,459.15 -2.73%
BNB $749.64 +4.29%
XRP $1.41 -3.17%
SOL $102.63 -1.56%
TRX $0.3328 +1.46%
DOGE $0.0859 -1.94%
ADA $0.2133 -4.47%
BCH $252.03 -2.88%
LINK $11.84 -1.85%
HYPE $84.73 -2.25%
AAVE $130.03 -3.33%
SUI $0.7868 +1.26%
XLM $0.1832 -1.31%
ZEC $1,007.60 +0.35%
BTC $79,703.19 -1.82%
ETH $2,459.15 -2.73%
BNB $749.64 +4.29%
XRP $1.41 -3.17%
SOL $102.63 -1.56%
TRX $0.3328 +1.46%
DOGE $0.0859 -1.94%
ADA $0.2133 -4.47%
BCH $252.03 -2.88%
LINK $11.84 -1.85%
HYPE $84.73 -2.25%
AAVE $130.03 -3.33%
SUI $0.7868 +1.26%
XLM $0.1832 -1.31%
ZEC $1,007.60 +0.35%

Sonnet Biotherapeutics가 주주 승인을 받아 Hyperliquid Strategies Inc와 사업 합병을 진행합니다

2025-12-02 22:26:45

시장 소식에 따르면, 나스닥 상장 생명공학 회사 Sonnet Biotherapeutics가 주주 승인을 받아 Hyperliquid Strategies Inc와 사업 합병을 추진하고 있습니다.

이전 소식에 따르면, Hyperliquid Strategies는 S-1 문서를 제출하여 최대 10억 달러를 모금하거나 HYPE 토큰을 구매할 계획입니다.

app_icon
ChainCatcher Building the Web3 world with innovations.